2 January 2014
Smiths Medical has gained a key US Food and Drug Administration (FDA) approval for a customisable infusion system that helps maintain effective epidural analgesia during labour and delivery or with post-operative pain management.
The FDA 510(k) clearance allows Smiths Medical to market its CADD®-Solis pain management system version 3.0 with Programmed Intermittent Bolus (PIB) and Patient Controlled Analgesics (PCA) delivery in the United States.
PIB medication delivery, using the CADD®-Solis v3.0, consistently administers programmed intermittent boluses (doses) that can be supplemented by the patient, improving pain relief and reducing the need for clinical interventions.
The CADD®-Solis ambulatory infusion system, designed for nurses, anesthesiologists, pharmacists and other hospital personnel, is a state-of-the-art system that meets industry recognised standards for advanced error-reduction features in PCA pumps.
General media enquiries
Contact our global media and communications team at:

Please note – the press team can only answer enquiries from accredited members of the press.
Related articles

Annual Results for the year ended 31 July 2025
Find out more
Smiths Detection selected as security technology provider to International Airport Heraklion Crete
Read our latest company news as Smiths Detection announces selection to supply a suite of leading security screening solutions to International Airport Heraklion Crete
Find out more
John Crane unveils game-changing mechanical seal, setting new benchmark for ethane pipeline performance
Read our company news as John Crane has launched a new mechanical seal
Find out more